Facetten
Zugriff
Einrichtung
Medientyp
- Text 7
Karte
Erscheinungsjahr
Autor/in
- Mateos, Maria-Victoria
- Weisel, Katja 4
- Cavo, Michele 3
- Delforge, Michel 3
- Moreau, Philippe 3
- alle zeigen
Sprache
- Englisch 7
7 Einträge gefunden
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
- Ludwig, Heinz
- Terpos, Evangelos
- van de Donk, Niels
- Mateos, Maria-Victoria
- Moreau, Philippe
- Dimopoulos, Melitios-Athanasios
- Delforge, Michel
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- Mateos, Maria-Victoria
- Weisel, Katja
- De Stefano, Valerio
- Goldschmidt, Hartmut
- Delforge, Michel
- Mohty, Mohamad
- Cavo, Michele
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
- Ludwig, Heinz
- Sonneveld, Pieter
- Facon, Thierry
- San-Miguel, Jesus
- Avet-Loiseau, Hervé
- Mohty, Mohamad
- Mateos, Maria-Victoria
-
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
- Weisel, Katja
- Mateos, Maria-Victoria
- Gay, Francesca
- Delforge, Michel
- Cook, Gordon
- Szabo, Zsolt
- Desgraz, Renaud
-
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
- Mateos, Maria-Victoria
- Spencer, Andrew
- Nooka, Ajay K
- Pour, Ludek
- Weisel, Katja
- Cavo, Michele
- Laubach, Jacob P
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- Dimopoulos, Meletios
- Quach, Hang
- Mateos, Maria-Victoria
- Landgren, Ola
- Leleu, Xavier
- Siegel, David
- Weisel, Katja
-